References
1. Smith PF, Dodds M, Bentley D, Yeo K. Dosing will be a key success factor in repurposing antivirals for COVID-19. Br J Clin Pharmacol 2020; Apr 17. doi: 10.1111/bcp.14314.
2. Back DJ & Marzolini C. The challenge of HIV treatment in an era of polypharmacy. J Int AIDS Soc. 2020; 23, e25449.
3. http://www.hiv-druginteractions.org (2020). Accessed April 28th 2020
4. http://www.CredibleMeds.org (2020). Accessed April 28th 2020.
5. Kaletra® prescribing information (April 2020). Accessed April 28th 2020
6. Borba MGS, Val FFA, Sampaio VS et al. Effect of high vs low dose chloroquine diphosphate as adjunctive therapy for patients hospitalised with severe respiratory syndrome coronavirus 2 (Sars-Cov-2) infection: A randomised clinical trial. JAMA Netw Open 2020; April 1: 3 (4) e208857.
7. Chorin E, Dai M, Shulman E et al. The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin. Nat Med 2020; https://doi.org/10.1038/s41591-020-0888-2.
8. EMEA news release April 23rd 2020. http://www.ema.europa.eu.
9. FDA drug safety communication. April 24th 2020. http://www.fda.gov/safety
10. http://www.medsafetyscan.org. Accessed April 28th 2020.
11. http://www.covid19-druginteractions.org. Accessed April 28th 2020.